Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations

Biomaterials

Volumn 35, Issue 7, 2014, Pages 2264-2271

  Charoen, Kristie M ^a   Fallica, Brian ^a   Colson, Yolonda L ^b   Zaman, Muhammad H ^a   Grinstaff, Mark W ^a,c  

^a Boston University   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c USA   (United States)

Author keywords

3D cell culture; Cancer model; Cell migration; Collagen; Drug delivery; Spheroid; Tumor mimic

Indexed keywords

3-D CELL CULTURE; CANCER MODELING; CELL MIGRATION; DEVELOPMENT PROGRAMS; MULTICELLULAR AGGREGATES; MULTICELLULAR SPHEROID; MURINE XENOGRAFT MODEL; SPHEROID;

BIOMIMETICS; CELL CULTURE; COLLAGEN; DIAGNOSIS; DISEASES; DRUG DELIVERY; NANOPARTICLES; TUMORS;

THREE DIMENSIONAL;

COLLAGEN GEL; NANOPARTICLE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMIMETICS; BONE CANCER; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCREENING; TUMOR SEEDING; TUMOR SPHEROID; TUMOR XENOGRAFT;

MURINAE;

3D CELL CULTURE; CANCER MODEL; CELL MIGRATION; COLLAGEN; DRUG DELIVERY; SPHEROID; TUMOR MIMIC;

ANTINEOPLASTIC AGENTS; BIOMIMETICS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EQUIPMENT AND SUPPLIES; HUMANS; IMAGING, THREE-DIMENSIONAL; MICROSPHERES; NEOPLASMS;

EID: 84891371895     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.038     Document Type: Article

References (55)

1. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nature Mater 2010, 9:90-93.
2. Fallica B., Makin G., Zaman M.H. Bioengineering approaches to study multidrug resistance in tumor cells. Integr Biol 2011, 3(5):529-539.
3. Birgersdotter A., Sandberg R., Ernberg I. Gene expression perturbation invitro - a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol 2005, 15(5):405-412.
4. Dhiman H.K., Ray A.R., Panda A.K. Characterization and evaluation of chitosan matrix for invitro growth of MCF-7 breast cancer cell lines. Biomaterials 2004, 25(21):5147-5154.
5. Dhiman H.K., Ray A.R., Panda A.K. Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials 2005, 26(9):979-986.
6. Wang X., Sun L., Maffini M.V., Soto A., Sonnenschein C., Kaplan D.L. Acomplex 3D human tissue culture system based on mammary stromal cells and silk scaffolds for modeling breast morphogenesis and function. Biomaterials 2010, 31(14):3920-3929.
7. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., et al. Engineering tumors with 3D scaffolds. Nature Methods 2007, 4(10):855-860.
8. Pampaloni F., Reynaud E.G., Stelzer E.H.K. The third dimension bridges the gap between cell culture and live tissue. Nature Rev Mol Cell Biol 2007, 8:839-845.
9. Martin K.J., Patrick D.R., Bissell M.J., Fournier M.V. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008, 3(8):e2994.
10. Weaver V.M., Petersen O.W., Wang F., Larabell C., Briand P., Damsky C., et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and invivo by integrin blocking antibodies. JCell Biol 1997, 137(1):231-245.
11. Kim J.B., Stein R., O'Hare M.J. Three-dimensional invitro tissue culture models of breast cancer - a review. Breast Cancer Res Treat 2004, 85(3):281-291.
12. Fallica B., Maffei J.S., Villa S., Makin G., Zaman M. Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels. PLoS ONE 2012, 7(10):e48024.
13. Gurski L.A., Jha A.K., Zhang C., Jia X., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for invitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30(30):6076-6085.
14. Tibbitt M.W., Anseth K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol Bioeng 2009, 103(4):655-663.
15. Hoffman A.S. Hydrogels for biomedical applications. Adv Drug Delivery Rev 2002, 54:3-12.
16. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31(32):8494-8506.
17. Carletti E., Motta A., Migliaresi C. Scaffolds for tissue engineering and 3D cell culture. 3D cell culture 2011, 17-39. Springer. J.W. Haycock (Ed.).
18. Ghajar C.M., Bissell M.J. Tumor engineering: the other face of tissue engineering. Tissue Eng Part A 2010, 16(7):2153-2156.
19. Friedrich J., Ebner R., Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 2007, 83(11-12):849-871.
20. Sutherland R.M., McCredie J.A., Inch W.R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. JNatl Cancer Inst 1971, 46(1):113-120.
21. Timmins N., Dietmair S., Nielsen L. Hanging-drop multicellular spheroids as a model of tumour angiogenesis. Angiogenesis 2004, 7:97-103.
22. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003, 83:173-180.
23. Santini M.T., Rainaldi G., Indovina P.L. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol 2000, 36:75-87.
24. St.Croix B. Cell adhesion and drug resistance in cancer: current opinion in oncology. Curr Opin Oncol 1997, 9:549-556.
25. Stein A.M., Demuth T., Mobley D., Berens M., Sander L.M. Amathematical model of glioblastoma tumor spheroid invasion in a three-dimensional invitro experiment. Biophys J 2007, 92(1):356-365.
26. Bell H.S., Wharton S.B., Leaver H.A., Whittle I.R. Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels. JNeurosurg 1999, 91(6):989-996.
27. Yip D., Cho C.H. Amulticellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem Biophys Res Commun 2013, 433:327-332.
28. Wiercinska E., Naber H.P., Pardali E., van der Pluijm G., van Dam H., ten Dijke P. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2011, 128(3):657-666.
29. Tamaki M., McDonald W., Amberger V.R., Moore E., Del Maestro R.F. Implantation of C6 astrocytoma spheroid into collagen type I gels: invasive, proliferative, and enzymatic characterizations. JNeurosurg 1997, 87(4):602-609.
30. Vamvakidou A.P., Mondrinos M.J., Petushi S.P., Garcia F.U., Lelkes P.I., Tozeren A. Heterogeneous breast tumoroids: an invitro assay for investigating cellular heterogeneity and drug delivery. JBiomol Screen 2007, 12(1):13-20.
31. Xue B., Wen C., Shi Y., Zhao D., Li C. Human NRAGE disrupts E-cadherin/β-catenin regulated homotypic cell-cell adhesion. Biochem Biophys Res Commun 2005, 336:247-251.
32. Frixen U.H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. JCell Biol 1991, 113:173-185.
33. Colby A., Colson Y., Grinstaff M.W. Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles. Nanoscale 2013, 5:3496-3504.
34. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. JNatl Cancer Inst 1990, 82(15):1247-1259.
35. Foa R., Norton L., Seidman A.D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994, 24(1):6-14.
36. ® and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977, 7(1):63-67.
37. Zaman M.H., Trapani L.M., Sieminski A.L., MacKellar D., Gong H., Kamm R.D., et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. PNAS 2006, 103(29):10889-10894.
38. Osborne C.S., Barbenel J.C., Smith D., Savakis M., Grant D.M.H. Investigation into the tensile properties of collagen/chondroitin-6-sulphate gels: the effect of crosslinking agents and diamines. Med Biol Eng Comput 1998, 36:129-134.
39. Sheu M.-T., Huang J.-C., Yeh G.-C., Ho H.-O. Characterization of collagen gel solutions and collagen matrices for cell culture. Biomaterials 2001, 22:1713-1719.
40. Liu R., Gilmore D.M., Zubris K.A.V., Xu X., Catalano P.J., Padera R.F., et al. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials 2012, 34:1810-1819.
41. Zubris K.A.V., Liu R., Colby A., Schultz M.D., Colson Y.L., Grinstaff M.W. Invitro activity of paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells. Biomacromolecules 2013, 14(6):2074-2082.
42. Substrate rigidity dictates phenotype, survival, and mechanics of primary human osteosarcoma cells. European Symposium on Biomedical Engineering 2008, E. Mylona, Z. Dailiana, X. Trepat, M. Lagoudakis (Eds.).
43. PaszeK M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8(3):241-254.
44. Yoshikawa H.Y., Cui J., Kratz K., Matsuzaki T., Nakabayashi S., Marx A., et al. Quantitative evaluation of adhesion of osteosarcoma cells to hydrophobic polymer substrate with tunable elasticity. JPhys Chem B 2012, 116(28):8024-8030.
45. Bachur N.R. Pharmacology of chemotherapeutic agents 1983, 13-22. Oral complications of cancer chemotherapy, Springer.
46. Bristow R.G., Hill R.P. Comparison between invitro radiosensitivity and invivo radioresponse in murine tumor cell lines II: invivo radioresponse following fractionated treatment and invitro/invivo correlations. Int J Radiat Oncol Biol Phys 1990, 18:331-345.
47. Malaise E.P., Fertil B., Chavaudra N., Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of invitro to invivo data. Int J Radiat Oncol Biol Phys 1986, 12:617-624.
48. Brzozowska K., Pinkawa M., Eble M.J., Müller W.-U., Wojcik A., Kriehuber R., et al. Invivo versus invitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. Int J Radiat Biol 2012, 88:405-413.
49. Santinit T., Rainaldi G. Multicellular tumour spheroids in radiation biology. Int J Radiat Biol 1999, 75:787-799.
50. Kunz-Schughart L.A. Multicellular tumor spheroids: intermediates between monolayer culture and invivo tumor. Cell Biol Int 1999, 23:157-161.
51. Rofstad E.K., Wahl A., Brustad T. Radiation response of multicellular spheroids initiated from five human melanoma xenograft lines. Relationship to the radioresponsiveness invivo. Br J Radiol 1986, 59:1023-1029.
52. Olive P.L., Durand R.E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994, 13:121-138.
53. Hirschberg H., Sun C.-H., Tromberg B.J., Yeh A.T., Madsen S.J. Enhanced cytotoxic effects of 5-aminolevulinic acid-mediated photodynamic therapy by concurrent hyperthermia in glioma spheroids. JNeurooncol 2004, 70(3):289-299.
54. Boyd M., Mairs S., Stevenson K., Livingstone A., Clark A., Ross S., et al. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. JGene Med 2002, 4(5):567-576.
55. Ballangrud Ö.M., Yang W.-H., Palm S., Enmon R., Borchardt P.E., Pellegrini V.A., et al. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids efficacy versus HER2/neu expression. Clin Cancer Res 2004, 10(13):4489-4497.